E
Eric K. Rowinsky
Researcher at ImClone Systems
Publications - 168
Citations - 22808
Eric K. Rowinsky is an academic researcher from ImClone Systems. The author has contributed to research in topics: Chemotherapy & Topotecan. The author has an hindex of 60, co-authored 165 publications receiving 21969 citations. Previous affiliations of Eric K. Rowinsky include University of Texas at San Antonio & Eli Lilly and Company.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner,Paul M. Harari,Jordi Giralt,Nozar Azarnia,Dong M. Shin,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,Jacek Jassem,Roger Ove,Merrill S. Kies,José Baselga,Hagop Youssoufian,Nadia Amellal,Eric K. Rowinsky,Eric K. Rowinsky,K. Kian Ang +17 more
TL;DR: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
Journal ArticleDOI
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
James A. Bonner,Paul M. Harari,Jordi Giralt,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,José Baselga,Sharon A. Spencer,Junming Zhu,Hagop Youssoufian,Eric K. Rowinsky,K. Kian Ang +12 more
TL;DR: Overall survival was significantly improved in those who experienced an acneiform rash of at least grade 2 severity compared with patients with no rash or grade 1 rash, confirming cetuximab plus radiotherapy as an important treatment option in this group of patients.
Journal ArticleDOI
Taxol: A Novel Investigational Antimicrotubule Agent
TL;DR: Taxol's unique mechanism of action, its spectrum of preclinical antitumor activity, and tumor responses in early clinical trials have generated renewed interest in pursuing its development.
Journal ArticleDOI
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
William P. McGuire,Eric K. Rowinsky,Neil B. Rosenshein,Francis C. Grumbine,David S. Ettinger,Deborah K. Armstrong,Ross C. Donehower +6 more
TL;DR: To assess the activity of taxol in patients with advanced, progressive, and drug-refractory ovarian cancer and to delineate more clearly the toxicity ofTaxol in this patie...
Journal ArticleDOI
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
Roman Perez-Soler,Abraham Chachoua,Lisa A. Hammond,Eric K. Rowinsky,Mark S. Huberman,Daniel D. Karp,James Rigas,Gary M. Clark,Pedro Santabarbara,Philip Bonomi +9 more
TL;DR: Erlotinib was active and well tolerated in this patient population, and further clinical development is clearly warranted; cutaneous rash seems to be a surrogate marker of clinical benefit, but this finding should be confirmed in ongoing and future studies.